Potential bioactive compounds and mechanisms of Fibraurea recisa Pierre for the treatment of Alzheimer's disease analyzed by network pharmacology and molecular docking prediction.

Introduction: Heat-clearing and detoxifying Chinese medicines have been documented to have anti-Alzheimer's disease (AD) activities according to the accumulated clinical experience and pharmacological research results in recent decades. In this study, Fibraurea recisa Pierre (FRP), the classic type of Heat-clearing and detoxifying Chinese medicine, was selected as the object of research. Methods: 12 components with anti-AD activities were identified in FRP by a variety of methods, including silica gel column chromatography, multiple databases, and literature searches. Then, network pharmacology and molecular docking were adopted to systematically study the potential anti-AD mechanism of these compounds. Consequently, it was found that these 12 compounds could act on 235 anti-AD targets, of which AKT and other targets were the core targets. Meanwhile, among these 235 targets, 71 targets were identified to be significantly correlated with the pathology of amyloid beta (Aß) and Tau. Results and discussion: In view of the analysis results of the network of active ingredients and targets, it was observed that palmatine, berberine, and other alkaloids in FRP were the key active ingredients for the treatment of AD. Further, Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis revealed that the neuroactive ligand-receptor interaction pathway and PI3K-Akt signaling pathway were the most significant signaling pathways for FRP to play an anti-AD role. Findings in our study suggest that multiple primary active ingredients in FRP can play a multitarget anti-AD effect by regulating key physiological processes such as neurotransmitter transmission and anti-inflammation. Besides, key ingredients such as palmatine and berberine in FRP are expected to be excellent leading compounds of multitarget anti-AD drugs.

Carboxymethylpachymaran entrapped plant-based hollow microcapsules for delivery and stabilization of ß-galactosidase.

ß-Galactosidase (ß-Gal) as a dietary supplement can alleviate symptoms of lactose intolerance. However, ß-Gal is deactivated due to the highly acidic conditions and proteases in the digestive tract. In this work, ß-Gal was encapsulated into L. clavatum sporopollenin exine capsules (SECs) to fabricate an oral-controlled release system and increase the stability of ß-Gal in the digestive tract. The SEC extraction process was optimized. A 3-hour vacuum loading was determined as the optimal loading time. Five different initial ratios of SECs : ß-Gal were optimized with the maximum enzyme retention rate reaching 79.40 ± 1.96%. Furthermore, ß-Gal-loaded SECs entrapped in carboxymethylpachymaran (CMP) could control the release of ß-Gal under simulated gastrointestinal conditions (SGC). The optimal enzyme retention rate reached 65.33 ± 1.46% within 24 h under SGC. Collectively, these results indicated that the entrapped SECs could be used as an effective oral delivery vehicle of ß-Gal to improve its performance as a dietary supplement in the digestion of lactose.

Nanoparticle Encapsulation Strategy: Leveraging Plant Exine Capsules Used as Secondary Capping for Oral Delivery.

Protein-based nanoparticles (NPs) with favorable properties including enhanced absorptivity and low toxicity still suffer a major challenge for rapid nutraceutical or drug release after oral administration. Hence, we introduced a secondary encapsulation for unstable factor to attain a controlled-release effect in a gastrointestinal environment. In this work, assembled nanoparticles engineered by nobiletin (NOB), zein, and tannin acid (TA) were first reported for drug delivery systems. The TA added was capable of obtaining further assembly to stabilize nobiletin in comparison with NOB-loaded zein NPs only. Sunflower pollens (SPGs) were selected as carriers for further oral delivery, while zein was chosen as a coating material for capping SPGs absolutely. As a result, the NOB/zein/TA NPs (NZT NPs) obtained had a stable size of 100 nm after 48 h. Besides, they could improve the chemical stability of NOB for at least 120 days at 4 °C compared with zein NPs (ZT NPs). Owing to the secondary capping by SPGs, the final system was able to release selectively via an oral route, that is, achieving no release in a gastric environment and slow release in an intestine environment. Generally, our research proposed a secondary protection model to prevent drug-loaded NPs from resolving after oral administration, which provided a new perspective for nutraceutical or drug encapsulation and controlled-release delivery.